Press "Enter" to skip to content

Although product pipelines are drying up.

Although product pipelines are drying up, the emergence of fresh markets, coupled with the arrival of personalized medication and other advances, give exciting possibilities for drugmakers. And, given the unpredictable drug-development environment, analysts are keeping a watchful vision as a ‘tale of two CEOs’ unfolds at two top pharmaceutical firms. One leadership change seems to show a business sticking with a carefully plotted course.Kohan, M.D., Ph.D., Professor of Medication, Division of Nephrology, University of Utah Wellness Sciences Center, Salt Lake City, Utah and lead investigator for the study. ‘These study results are encouraging and suggest that atrasentan may possess an additional therapeutic function for albuminuria reduction on top of the current standard of care for patients with type 2 diabetes.’ ‘The impact of persistent kidney disease is a growing global public health concern but few developments in treatment have been made in the last decade that positively have an effect on outcomes for individuals with this progressive disease,’ stated James Stolzenbach, Ph.D., divisional vice president, Dyslipidemia and Renal, Abbott.